Impact of CYP3A4 and CYP3A5 Genetic Variants on Tacrolimus Dosing and Therapeutic Outcomes in Kidney Transplant Recipients

Authors

  • Hafiza Fareeha Bashir Department of Biotechnology, Lahore College for Women University Lahore Pakistan
  • Rasheeda Bashir Department of Biotechnology, Lahore College for Women University Lahore, Pakistan
  • Farheen Aslam Department of Biotechnology, Lahore College for Women University Lahore, Pakistan
  • Sana Rafaqat Department of Biotechnology, Lahore College for Women University Lahore, Pakistan
  • Amina Latif Department of Biotechnology, Lahore College for Women University Lahore, Pakistan
  • Areej Fatima Department of Biotechnology, Lahore College for Women University Lahore, Pakistan
  • Zunaira Tahir Department of Biotechnology, Lahore College for Women University Lahore, Pakistan

DOI:

https://doi.org/10.15395/mkb.v58.4879

Keywords:

CYP3A4, CYP3A5, kidney transplant, pharmacogenetics, Pakistan, tacrolimus

Abstract

Tacrolimus is the cornerstone of immunosuppressive therapy in kidney transplantation; however, its narrow therapeutic index and variable metabolism make dose optimization difficult. Genetic variations in the CYP3A4 and CYP3A5 genes significantly influence tacrolimus metabolism yet limited data are available for Pakistani population. This study aimed to evaluate the association of CYP3A4 and CYP3A5 polymorphisms with tacrolimus dose requirements and post-transplant outcomes in Pakistani kidney transplant recipients.  A case-control study was conducted from January 2022 to December 2022 at Shaikh Zayed Hospital and Pakistan Kidney and Liver Institute. A total of 240 participants, including renal transplant recipients and controls, were enrolled using non-probability purposive sampling. Genotyping of CYP3A4 and CYP3A5 variants was performed using Tetra ARMS-PCR. Clinical data regarding tacrolimus dose requirements and rejection episodes were collected, and statistical analysis was performed using the SPSS version 25. Among the participants, 190 (79.1%) were male and 50 (20.9%) were female. Renal transplant recipients receiving tacrolimus accounted for 57% of the study population, while 43% were controls. Patients with the CYP3A5 expressor genotype required significantly higher tacrolimus doses to achieve target trough concentrations compared to non-expressors (OR=4.060, 95% CI: 2.455–6.715, p<0.001). The CC genotype of rs10264272 was associated with increased tacrolimus dose requirements, whereas AT and TT genotypes of rs413003343 were linked to lower dose requirements and better graft outcomes. These findings suggest that CYP3A4 and CYP3A5 genotyping may support individualized tacrolimus therapy in Pakistani kidney transplant recipients.

Downloads

Download data is not yet available.

References

1. Asghar RS, Saleem J, Javaid U, Zahoor M, Aziz F. Ten-year review of renal transplants in Punjab Province, Pakistan. East Mediterr Health J. 2025;31(3):191–7. doi:10.26719/2025.31.3.191

2. Knechtle SJ, Marson LP, editors. Kidney transplantation: principles and practice. 9th ed. Philadelphia, PA: Elsevier; 2024.

3. Lloberas N, Vidal-Alabró A, Colom H. Customizing tacrolimus dosing in kidney transplantation: focus on pharmacogenetics. Ther Drug Monit. 2025;47(1):141–51. doi:10.1097/FTD.0000000000001289

4. Zhao YC, Sun ZH, Li JK, Liu HY, Zhang BK, Xie XB, et al. Individualized dosing parameters for tacrolimus in the presence of voriconazole: a real-world PopPK study. Front Pharmacol. 2024;15:1439232. doi:10.3389/fphar.2024.1439232

5. Xajil-Ramos LY, Gándara-Mireles JA, Vargas Rosales RJ, Sánchez García OK, Ruano Toledo AM, Aldana de la Cruz AK, et al. Impact of CYP3A51 and CYP3A53 single nucleotide variants on tacrolimus pharmacokinetics and graft rejection risk in pediatric kidney transplant patients. Front Pharmacol. 2025;16:1592134. doi:10.3389/fphar.2025.1592134

6. Wanas H, Kamel MH, William EA, Fayad T, Abdelfattah ME, Elbadawy HM, et al. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients. J Clin Lab Anal. 2023;37(19–20):e24969. doi:10.1002/jcla.24969

7. Raj TY, Fernando ME, Sujit S, Valavan KT, Harshavardhan TS, Ramanathan A. Efficacy and outcomes of CYP3A5 genotype-based tacrolimus dosing compared to conventional body weight-based dosing in living donor kidney transplant recipients. Indian J Nephrol. 2022;32(3):240–6. doi:10.4103/ijn.IJN_278_20

8. Tanaka R, Suzuki Y, Watanabe H, Fujioka T, Hirata K, Shin T, et al. Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease. Clin Transl Sci. 2021;14(5):2034–42. doi:10.1111/cts.13065

9. Oetting WS, Wu B, Schladt DP, Guan W, Remmel RP, Dorr C. Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018;19(1):175–84. doi:10.2217/pgs-2017–0187

10. Balwani M. Clinical textbook of kidney transplant immunology. Chennai, India: Notion Press; 2025.

11. Tamashiro EY, Felipe CR, Genvigir FD, Rodrigues AC, Campos AB, Hirata RD, et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metab Pers Ther. 2017;32(2):89–95. doi:10.1515/dmpt-2016–0036

12. Rotarescu CA, Maruntelu I, Rotarescu I, Constantinescu AE, Constantinescu I. Single nucleotide polymorphisms of CYP3A4 and CYP3A5 in Romanian kidney transplant recipients: effect on tacrolimus pharmacokinetics in a single-center experience. J Clin Med. 2024;13(7):1968. doi:10.3390/jcm13071968

13. Hannachi I, Chadli Z, Kerkeni E, Kolsi A, Hammouda M, Chaabane A, et al. Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients. Pharmacogenomics J. 2021;21(1):69–77. doi:10.1038/s41397–020–00179–4

14. Xuan NT, Hop VQ, Kien TQ, Toan PQ, Thang LV, Binh HT, et al. Frequencies and association of CYP3A5 polymorphism with tacrolimus concentration among renal transplant recipients in Vietnam. Transplant Proc. 2022;54(8):2140–6. doi:10.1016/j.transproceed.2022.07.009

15. Nissenson AR, Fine RN, Mehrotra R, Zaritsky J, editors. Handbook of dialysis therapy e-book. 6th ed. Philadelphia: Elsevier Health Sciences; 2022.

16. Alatorre-Moreno EV, Saldaña-Cruz AM, Pérez-Guerrero EE, Morán-Moguel MC, Contreras-Haro B, López-de La Mora DA, et al. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T polymorphisms with tacrolimus dose, serum concentration, and biochemical parameters in Mexican patients with kidney transplant. Genes (Basel). 2024;15(4):497. doi:10.3390/genes15040497

17. Khan AR, Raza A, Firasat S, Abid A. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis. Pharmacogenomics J. 2020;20(4):553–62. doi:10.1038/s41397–019–0144–7

18. Colvin RB, Chang A, Cornell LD. Diagnostic pathology: kidney diseases e-book. 3rd ed. Philadelphia: Elsevier Health Sciences; 2023.

19. Chen L, Prasad GR. CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment. Pharmacogenomics Pers Med. 2018;11:23–33. doi:10.2147/PGPM.S107710

20. Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013;23(5):251–61. doi:10.1097/FPC.0b013e32835fcbb6

21. Hariharan S, editor. Long-term care of kidney transplant patients. Oxford University Press; 2024.

22. Wanas H, Kamel MH, William EA, Fayad T, Abdelfattah ME, Elbadawy HM, et al. The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients. J Clin Lab Anal. 2023;37:e24969. doi:10.1002/jcla.24969

23. Charfi R, Bacha MM, Ben Fadhal M, Ferchichi K, El Jebari H, Gaies E, et al. The effects of the CYP3A5*3 variant on tacrolimus pharmacokinetics and outcomes in Tunisian kidney transplant recipients. Tunis Med. 2023;101(10):738–44.

24. Alam A, Amanullah F, Baig-Ansari N, Lotia-Farrukh I, Khan FS. Prevalence and risk factors of kidney disease in urban Karachi: baseline findings from a community cohort study. BMC Res Notes. 2014;7(1):179. doi:10.1186/1756–0500–7–179

25. Khan AR, Raza A, Firasat S, Abid A. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis. The Pharmacogenomics Journal. 2020;20(4):553–62.

Downloads

Published

2026-06-30

Issue

Vol. 58 No. 2 (2026)

Section

Articles

License

Copyright (c) 2026 Majalah Kedokteran Bandung

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Under this license, authors retain copyright and grant Majalah Kedokteran Bandung the right of first publication. Others may share, remix, and adapt the work for non-commercial purposes, provided that appropriate credit is given to the author and to Majalah Kedokteran Bandung as the initial place of publication.

For details, please see: https://creativecommons.org/licenses/by-nc/4.0/

 

How to Cite

Impact of CYP3A4 and CYP3A5 Genetic Variants on Tacrolimus Dosing and Therapeutic Outcomes in Kidney Transplant Recipients. (2026). Majalah Kedokteran Bandung, 58(2), 123-131. https://doi.org/10.15395/mkb.v58.4879